- Wall Street returns to gains following the bill that sparks hope for the end of government shutdown.
- Tech stocks lead rally, recovering almost all of recent losses.
- Potential changes to Obamacare weigh on health insurers.
- Wall Street returns to gains following the bill that sparks hope for the end of government shutdown.
- Tech stocks lead rally, recovering almost all of recent losses.
- Potential changes to Obamacare weigh on health insurers.
Wall Street rebounded sharply on Monday after the U.S. Senate passed a bipartisan deal to end the record 40-day government shutdown — the first major step toward reopening federal agencies. Futures on U.S. indices have regained nearly all of the past two sessions’ losses, with improving sentiment also reflected across crypto and bond markets (US100: +1.5%, US2000: +1.4%, US500: +0.9%, US30: +0.4%).
The U.S. government shutdown, now 41 days long, has left 1.4 million federal workers unpaid and disrupted key services, including air travel and food aid for 41 million Americans. A bipartisan Senate deal provides temporary funding through January 30, full-year appropriations for some agencies and back pay for federal employees.
However, several Democrats, including Senators Schumer and Warren, have already opposed it, citing lack of action on expiring healthcare subsidies, which are now scheduled for a December vote. The package also reimburses states for SNAP and WIC costs during the shutdown, but still faces hurdles in the House before reaching President Trump’s desk.
Tech stocks are championing today’s rally, with Mag7 driving significant gains in main U.S. indices. Nvidia is the biggest gainer in the group (NVDA.US: +3.6%), followed by Alphabet (GOOGL.US: +3.3%), Tesla (TSLA.US: +2.7%) and Amazon (AMZN.US: +2%). Significant gains are also seen in the other semiconductor stocks (AMD.US: +5.4%, MU.US: +7.1%, INTC.US: +2.5%).
The optimism is market-broad today, with defensive sectors (Consumer staples, Energy, Health services) giving up some in favour of more risk/growth-oriented stocks. Source: Bloomberg Finance LP.
US100 (D1)
Nasdaq 100 futures rebounded strongly today, hovering just 0.3% below recouping losses from the past two sessions. The index has returned above recent resistance near 25,375 points and is attempting to leverage bullish momentum to break above its 10-day exponential moving average. With the price approaching the center of its typical trading range and a neutral RSI around 55, investors have room to adjust amid the latest government shutdown news and ongoing earnings season, with Nvidia in focus this week.
Source: xStation5
Company news:
-
Health insurer stocks fell Monday after former President Donald Trump called for redirecting Obamacare subsidies directly to consumers. Shares of Centene slid 8.4%, Elevance Health 1.6%, and UnitedHealth 0.3%. The subsidies, set to expire year-end, were introduced during the pandemic to help low-income Americans but are now central to a 40-day federal shutdown over healthcare funding.
-
Monday.com shares plunged 16% despite record third-quarter results and a sharp narrowing of losses. Revenue rose 26% to $317 million, beating guidance, while adjusted operating profit hit a record $47.5 million. The company maintained its full-year forecast, but investor concerns over AI’s impact on workplace software continue to weigh on sentiment. The pessimism is driven by a narrowed full-year revenue forecast.
-
Nvidia (NVDA.US) CEO Jensen Huang requested more chip supplies from TSMC during a visit to Taiwan, raising robust AI demand. He credited TSMC’s support as vital to Nvidia’s success, noting all major AI memory suppliers have expanded capacity. Despite recent pressure on megacap tech stocks amid AI skepticism, Nvidia remains the world’s most valuable company. TSMC’s CEO C.C. Wei expects record sales to continue as demand outpaces supply.
-
Pfizer (PFE.US: +1%) clinched a $10 billion deal to acquire obesity drug developer Metsera, defeating Novo Nordisk in a heated bidding war. Metsera accepted Pfizer’s offer citing antitrust risks in Novo’s bid (NOVOB.DK: +2.2%). The deal gives Pfizer a long-sought foothold in the booming weight-loss drug market, though Metsera’s treatments are still years from launch. Novo said it will focus on advancing its own obesity pipeline.
-
Rumble (RMBL.US) shares jumped 9% after the video platform narrowed its third-quarter net loss to $16.3 million from $31.5 million a year earlier and boosted average revenue per user by 7% to $0.45. Revenue slipped slightly to $24.8 million, while monthly active users fell to 47 million. Investors welcomed signs of improved monetization and cost control despite user decline.
Omnicom and Interpublic Join Forces. Will the Merger Be Enough to Catch Up with Big Tech?
Has Alphabet just won the AI race?
Crypto news: Bitcoin stabilizes after the sell-off 📈December Fed rate cut odds rise
Chart of the day: OIL.WTI (24.11.2025)
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.